|
|
 |
 |
|
70 years exclusively dedicated to animal health.
Passionate about animals - past, present and for the future.
Vétoquinol has come a long way since its inception in 1933. The company was founded by Joseph Frechin: a pharmacist and veterinarian's son, who used quinoline - traditionally associated with human medicine - to treat animals. From its innovative beginnings our company today still maintains a passion for animals and their health and a strong desire to remain independent.
Some important steps in the evolution of this family-owned company, still managed today by the founder’s son, Etienne Frechin.
|
 |
| 1933-1985: The Start |
| 1933 |
 |
Laboratoires Biochimiques de l'Est set up. |
| 1952 |
|
Vétoquinol logo created. |
| 1962 |
|
Renamed "Vétoquinol S.A", facilities transfer from Lure (Haute Saône) to Magny-Vernois. |
| 1975 |
|
New French laws on veterinary pharmaceutical products in line with European directives come into force. |
| 1977 |
|
Vetam, 1st subsidiary abroad, in Holland. |
| 1980 |
|
"Research and Development" unit created. |
| 1984 |
|
Galvet Ltd set up in Ireland. |
| 1985 |
|
New investment in biotechnology with the take-over of IBA (Institut de Biologie Animale in Montélimar, France). |
| 1987-1995: The Development |
| 1987 |
|
Vétoquinol launches Tolfédine®, new product based on tolfenamic acid |
|
|
Vétoquinol acquires Psyphac, Belgium |
| 1990 |
|
Vétoquinol acquires Univet, UK. |
|
|
Creation of Vétoquinol North America (Canada) which in turn acquires Multivet and MVE, Canada. |
| 1991 |
|
Vétoquinol Biotechnologie created. |
|
|
Creation of a new manufacturing unit for products for injection. |
|
|
Vétoquinol acquires Antibioticos Pharma Vet in Spain, renamed Vétoquinol Espacialidades Veterinarias. |
| 1992 |
|
Vétoquinol Mexico founded. |
|
|
Vétoquinol North America acquires Austin and Dispar in Canada. |
| 1994 |
|
Acquisition of Immunovet in United States. |
| 1995 |
|
Vétoquinol launches Marbocyl®, new medicine based on marbofloxacin in Europe and Stomadhex in the United States. |
|
|
In Holland, Vetam becomes Vétoquinol BV. |
| 1998-2006: Faster Growth |
| 1998 |
|
Vétoquinol takes over MECA, Germany. |
| 1999 |
|
Vétoquinol acquires Webster, Canada. |
|
|
Vétoquinol wins "Les ECHOS Silver Trophy ", award - French financial daily newspaper. |
| 2000 |
|
New vaccine against Bovine pasteurellosis launched. |
| 2001 |
|
Vétoquinol acquires Chassot group. |
|
|
Vétoquinol launches Aurizon®, new ear medicine based on marbofloxacin. |
| 2002 |
|
Vétoquinol a player in the US market, acquires Evsco Pharmaceuticals and Tomlyn Products to form Vétoquinol USA. |
|
|
First international symposium for cardiology. |
|
|
Launch of Prilium®, first ACE inhibitor as oral solution to treat heart failure in dogs. |
| 2003 |
|
Capital opened to two minority financial institutions. |
|
|
Phenylpropanolamine (Propalin®) internationally launched. |
|
|
Marbocyl® available as palatable tablets. |
|
|
New research centre inaugurated. |
| 2004 |
|
Vétoquinol Shanghai office opened in Asia. |
|
|
New Vétoquinol signature launched: "Sign of Passion." |
| 2005 |
|
Enisyl-F, a lysine based nutritional supplement for Feline Herpes Virus infections and Epakitin, a chitosan based phosphate binder and uremic reducer for Chronic Kidney Disease in dogs and cats are launched in the USA. |
| 2006 |
|
Azodyl™ for azotemia in kidney disease is launched. |
|
|
Vétoquinol acquires VET Solutions dramatically increasing its US presence. |
| 2007 |
|
Vétoquinol introduces Vetprofen™ (Carprofen), its first prescription product in the US market providing added value for pets with osteoarthritis and post operative pain.
|
|
|
|
|
